Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in fk506-treated kidney transplant recipients

Transplantation

Volumn 89, Issue 11, 2010, Pages 1417-1423

  Sommerer, Claudia ^a   Zeier, Martin ^a   Meuer, Stefan ^a   Giese, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

FK506; NFAT regulated gene expression; Pharmacodynamic immune monitoring.; Renal transplantation; Tacrolimus

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MESSENGER RNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BLOOD LEVEL; FEMALE; GENE EXPRESSION REGULATION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADRENAL CORTEX HORMONES; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MYCOPHENOLIC ACID; NFATC TRANSCRIPTION FACTORS; T-LYMPHOCYTES; TACROLIMUS;

EID: 77953359811     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181dc13b6     Document Type: Article

References (37)

1. Radermacher J, Meiners M, Bramlage C, et al. Pronounced renal vaso-constriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506. Transpl Int 1998; 11: 3.
2. van Duijnhoven EM, Christiaans MH, Boots JM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002; 13: 213.
3. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
4. Margreiter R. Efficacy and safety of tacrolimus compared with ciclos-porin microemulsion in renal transplantation: A randomised multi-centre study. Lancet 2002; 359: 741.
5. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: A further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247.
6. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporinein the prevention of renal allograft rejection: A report of the European Tacrolimus Mul-ticenter Renal Study Group. Transplantation 1997; 64: 436.
7. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
8. Jiang H, Kobayashi M. Differences between cyclosporin A and tacroli-mus in organ transplantation. Transplant Proc 1999; 31: 1978.
9. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: A novel perspective for optimal individualized doses of cal-cineurin inhibitors. Nephrol Dial Transplant 2004; 19(suppl 4): IV55.
10. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: A novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77: 339.
11. Sommerer C, Morath C, Giese T, et al. Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients. Transplant Proc 2008; 40: 1416.
12. Sommerer C, Giese T, Schmidt J, et al. Ciclosporin A tapering moni-toredby NFAT-regulated gene expression: A new concept of individual immunosuppression. Transplantation 2008; 85: 15.
13. Konstandin MH, Sommerer C, Doesch A, et al. Pharmacodynamic cyclo-sporine A-monitoring: Relation of gene expression in lymphocytes to cy-closporine blood levels in cardiac allograft recipients. Transpl Int 2007; 20: 1036.
14. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006; 82: 1280.
15. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6(5 pt 2): 1111.
16. Chang SH, Russ GR, Chadban SJ, et al. Trends in kidney transplantation in Australia and New Zealand, 1993-2004. Transplantation 2007; 84:611.
17. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclos-porin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ2005; 331: 810.
18. Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795.
19. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
20. Chang SH, Russ GR, Chadban SJ, et al. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005. Nephrology (Carlton) 2008; 13: 171.
21. Almawi WY, Melemedjian OK. Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol Dial Transplant 2000; 15: 1916.
22. Matsuda S, Shibasaki F, Takehana K, et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep 2000; 1: 428.
23. Hauser IA, Koziolek M, Hopfer U, et al. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int 1998; 54: 1139.
24. Miller JL, Ericson SG. Cyclosporin A and tacrolimus (FK506) differentially alter T-cell receptor expression in vivo. Immunopharmacol Im-munotoxicol 2007; 29: 105.
25. Elbaz B, Alperovitch A, Gottesman MM, et al. Modulation of Na+-Ca2+ exchanger expression by immunosuppressive drugs is isoform-specific. Mol Pharmacol 2008; 73: 1254.
26. Cristillo AD, Bierer BE. Identification of novel targets of immunosuppressive agents by cDNA-based microarray analysis. J Biol Chem 2002; 277: 4465.
27. Morris R. Modes of action of FK506, cyclosporin A, and rapamycin. Transplant Proc 1994; 26: 3272.
28. Fukudo M, Yano I, Masuda S, et al. Distinct inhibitory effects of tacrolimus and cyclosporin A on calcineurin phosphatase activity. JPharma-colExp Ther2005; 312: 816.
29. Sommerer C, Hartschuh W, Enk A, et al. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008; 22: 549.
30. Mortensen DM, Koefoed-Nielsen PB, Jorgensen KA. Calcineurin activity in tacrolimus-treated renal transplant patients early after and 5 years after transplantation. Transplant Proc 2006; 38: 2651.
31. Fukudo M, Yano I, Masuda S, et al. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin Pharmacol Ther 2005; 78: 168.
32. Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation 2000; 70: 327.
33. Heitman J, Koller A, Kunz J, et al. The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae. Mol Cell Biol 1993; 13: 5010.
34. Marton MJ, DeRisi JL, Bennett HA, et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 1998; 4: 1293.
35. Duperrier K, Velten FW, Bohlender J, et al. Immunosuppressive agents mediate reduced allostimulatory properties of myeloid-derived dendritic cells despite induction of divergent molecular phenotypes. Mol Immunol 2005; 42: 1531.
36. Zeyda M, Geyeregger R, Poglitsch M, et al. Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-kappaB in immunological synapse formation. JLeukoc Biol 2007; 81: 319.
37. Sindhi R, Allaert J, Gladding D, et al. Cytokines and cell surface receptors as target end points of immunosuppression with cyclosporine A. J Interferon Cytokine Res 2001; 21: 507.